Here's what we'll cover
Here's what we'll cover
If you take Ozempic or Wegovy, you may have seen headlines about Novo Nordisk's shrinking share price and nervous investors. The stock has fallen sharply from its 2024 peak, and each recent update from the company has been met with selling rather than relief.
Those headlines are about the company's future profits. They are not a warning about your medication. Here is what is actually happening, and what it does and does not change for patients.
Why Investors Are Worried
Lilly Has Taken the Lead
Eli Lilly's tirzepatide, sold as Mounjaro and Zepbound, has overtaken semaglutide in the obesity market. Novo held about 39% of the obesity drug market in the second quarter of 2026 compared with about 61% for Lilly, according to Yahoo Finance. In the head to head SURMOUNT 5 trial, tirzepatide produced about 20% average weight loss versus about 14% for semaglutide over 72 weeks, and prescribers have noticed.
Guidance and Strategy That Underwhelmed
On August 4, 2026, Novo reported second quarter results that beat expectations, yet shares closed down 6% after Wegovy pill sales came in slightly below forecasts and injectable Wegovy sales fell about 22% from a year earlier, as reported by BioSpace and CNBC.
At its Capital Markets Day on September 21, 2026, the company said it expects 2026 adjusted sales to range from a 6% decline to flat at constant exchange rates, and it set 2030 goals that investors viewed as modest. Shares fell more than 5% that day. CEO Mike Doustdar called the coming loss of semaglutide patent protection, starting in the US in 2032, the "elephant in the room."
Lower Prices Mean Lower Revenue per Patient
Novo has cut US self pay prices and is betting on volume. That is good for patients but squeezes revenue per prescription, which investors read as pressure on profits.
Pipeline Setbacks
In November 2025, two large trials testing semaglutide in early Alzheimer's disease failed to slow progression, according to BioSpace. Investors had hoped those trials would open a major new market. Next generation candidates such as CagriSema remain in development.
What This Does Not Mean for You
None of this signals a shortage or a withdrawal. Novo remains highly profitable, semaglutide is widely available, and the company launched the Wegovy pill in the US in January 2026, with nearly 5 million prescriptions written by early August, according to BioSpace.
- Your Ozempic or Wegovy prescription is not at risk because of the stock price.
- Supply problems from 2022 to 2024 have been resolved, and semaglutide is off the FDA shortage list.
- Your dose, safety profile, and expected results are unchanged.
How Competition Is Already Helping Patients
Lower Self Pay Prices
The price war is real and patients are the beneficiaries. As of October 2026, manufacturer self pay prices start around $149 per month for the lowest dose of the Wegovy pill and about $199 for the first fills of the Wegovy pen, with Zepbound starting at about $299 through LillyDirect. That is a fraction of the $1,000 plus list prices patients faced in 2024. Check current offers and GLP-1 coupons and savings programs before you fill.
| Medication | Typical self pay starting price (Oct 2026) | Format |
|---|---|---|
| Wegovy pill | About $149 per month at the lowest dose | Daily tablet |
| Wegovy pen | About $199 for initial doses, $349 at maintenance | Weekly injection |
| Zepbound | About $299 at the starting dose | Weekly injection |
| Foundayo (orforglipron) | About $149 to start | Daily tablet |
Prices vary by dose and channel and change often, so confirm the current amount before you buy.
More Choices
Patients now choose between injectable and oral semaglutide, tirzepatide, and Lilly's oral Foundayo. Different people respond differently, so more options make it easier to find a medication you tolerate and can afford.
Broader Coverage
Competition has also helped open public coverage. Since July 1, 2026, eligible Medicare Part D enrollees can get Wegovy, Zepbound, or Foundayo for a $50 monthly copay through the temporary Medicare GLP-1 Bridge, which runs through December 31, 2027.
The Compounding Question
Cheap compounded semaglutide once undercut Novo's brand. That channel is narrowing. Semaglutide left the FDA shortage list in February 2025, and on April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of substances large outsourcing pharmacies may use for bulk compounding. If you use a compounded product, ask your provider now about a plan for switching to an approved medication, since brand self pay prices are now much closer to compounded prices than they were.
What to Do Now
- Stay on your current medication unless your prescriber advises a change.
- Compare your out of pocket cost with current manufacturer self pay prices; you may be overpaying.
- If you are on Medicare, ask whether you qualify for the GLP-1 Bridge.
- Ask your doctor whether semaglutide or tirzepatide is the better fit for your goals and side effect tolerance.
No waiting list. No insurance needed.
Frequently Asked Questions
Is Novo Nordisk in financial trouble?
No. Novo remains highly profitable. Investors are worried about slower growth, lower prices, competition from Eli Lilly, and semaglutide patents expiring in the US starting in 2032, not about the company's survival.
Will my Ozempic or Wegovy supply be affected?
There is no sign of that. Semaglutide is off the FDA shortage list and widely available. Stock market moves do not change manufacturing or your prescription.
Why is Eli Lilly gaining market share?
Tirzepatide (Mounjaro, Zepbound) produced more average weight loss than semaglutide in the head to head SURMOUNT 5 trial, and Lilly has expanded supply and lowered self pay prices.
Are GLP-1 medications getting cheaper?
Yes, for self pay patients. As of October 2026, manufacturer prices start around $149 per month for the lowest Wegovy pill dose and about $299 for starting doses of Zepbound.
Does Medicare cover Wegovy now?
Eligible Medicare Part D enrollees can get Wegovy, Zepbound, or Foundayo for $50 a month through the Medicare GLP-1 Bridge, which runs from July 1, 2026 to December 31, 2027. BMI and health condition criteria apply.
When will generic semaglutide be available in the US?
Novo's CEO has said US loss of exclusivity for semaglutide begins in 2032. Until then, brand products and manufacturer self pay programs are the main options.
The Bottom Line
Investor anxiety about Novo Nordisk is a business story about market share, pricing, and patents. For patients, the same forces are making GLP-1 treatment cheaper and easier to access: self pay prices have fallen sharply, oral options have arrived, and Medicare now offers a $50 copay bridge for eligible enrollees.
Your semaglutide prescription is not at risk because of the stock price. Focus on whether you are on the right medication at the best available price. To find a prescriber who can help you compare options, compare vetted telehealth providers. Always consult your physician before changing any medication.